MDS,Decitabineazacitidine

Koji Sasaki1, Elias Jabbour1, Guillermo Montalban-Bravo1

  • 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston.

NEJM evidence
|February 6, 2024
PubMed
概括

较低风险的骨髓发育综合征 (MDS) 用减弱剂量的低甲基化剂治疗,如德西他和阿扎丁,改善了结果,包括输血独立性,没有显著的副作用.